“The fact that they’re going after solving a problem that will have major impact in cancer care is hugely important and made it even more compelling for us to be involved,” Kopelman added. “It’s pretty rare to have a team like the one they’re building go after this kind of idea.”
科普曼补充说:“他们致力要解决的问题将对癌症治疗产生重大影响,这一点十分重要,也让我们产生了更强烈的投资兴趣。他们目前组建起来攻克这个难题的团队十分少有。”
There is a “seismic shift” happening toward evidence-based medicine, Snow said. “The number of possibilities for what a doctor should do about a health problem is getting unmanageable, he said, “especially in cancer, which is very complex.”
斯诺称,循证医学目前正发生着翻天覆地的变化。他说:“一个医生现在针对某个健康问题所能采取的治疗方案太多了,数量之大变得难以管理,尤其是癌症,因为这个领域十分复杂。”
Further complicating the process is the fact that so many cancer drugs in the pipeline are biomarked, Snow added, meaning that they are tailored to physiologically impact only certain groups of people, rather than the entire population.
斯诺还称,使治疗更趋复杂的问题是,目前渠道在售的很多癌症治疗药物都做过生物标记。这就意味着,它们都是度身定制,只对特定人群、而不是所有人有效。
【科技是否万能 大数据能够战胜癌症吗】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15